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e wish to thank Dr. Crossey et al1 for their letter, “An approach to insulin tapering and discontinuation after
glucagon-like peptide-1 receptor agonist initiation” in response to our original publication, “Real-world evaluation of
insulin requirements after GLP1 agonist or SGLT2 inhibitor
initiation and titration.” 2 The authors discussed titrating
glucagon-like peptide-1 receptor agonists (GLP1a) to the
maximum dose to allow for tapering and discontinuation of
insulin. This allows optimization of diabetes regimens to potentially reduce negative cardiorenal outcomes as well as minimize the risk of hypoglycemia, which is often associated with
insulin.3,4 Along with the cardiorenal benefits, the authors also
discussed the preference given to GLP1a in the 2022 updates to
the American Diabetes Association guidelines. This approach
may provide additional glycosylated hemoglobin (HbA1c) reduction without the need to use insulin and increase the risk
for hypoglycemia.5
Our study focused on the percentage of insulin dose reduction after GLP1a initiation. After 6 months, an average
dose reduction of 23.5% for the total insulin dose was found.
This study was conducted on patients from 2016 to 2019 and
did not include data from all GLP1a agents and doses currently approved (as of June 2022). The average baseline total
insulin dose was approximately 72 units, and the average
baseline HbA1c was 9.3%. Given these factors, this may have
prevented large dose reductions in or discontinuation of insulin as we aimed to reach goal HbA1c and patients did not
have access to the maximum doses of GLP1a available today.
However, even with these factors, we did find that bolus insulin was discontinued in 24 of 56 patients, approximately 43%.2
We agree that minimizing the amount of insulin use is
crucial, although for those who have uncontrolled blood
glucose levels and are already on insulin at baseline, this

may take longer than anticipated. Certain patients may be
able to handle adjusting insulin doses on their own with
specific instructions to follow when they experience hypoglycemia. These situations are ideal as this can allow for
improved safety and efficacy by avoiding hypoglycemia
and reaching the HbA1c target with minimal use of insulin
and optimal doses of GLP1a. Close monitoring of patients
is also vital; for patients who are unable to keep appointments or are not being closely followed (ie, those who are
prescribed a GLP1a and are not seen in the clinic until another 3-6 months have passed), a 6-month target for complete insulin discontinuation may not always be achievable.
However, this may be a possible consideration for those
who have lower baseline HbA1c and are on optimal doses of
GLP1a. Having regular appointments, especially within the
first few months after initiation, will ensure patient safety
and increase the likelihood of achieving this goal. Given the
variability in patient factors including response to GLP1a,
risk of hypoglycemia, and adherence to medications and
follow-up appointments, utilizing a more individualized
patient-specific approach would be most ideal from a safety
perspective than targeting a specific timeline of insulin
tapering or discontinuation.
As the authors discussed, the cardiovascular, metabolic,
and renal benefits of GLP1a, along with a favorable safety
profile, make these agents a preferred therapeutic option for
all eligible patients with diabetes. A long-term goal of tapering and discontinuing insulin should be strongly considered
for all patients with diabetes. A 6-month goal may be reasonable and more easily achieved for those who are closer
to their HbA1c goal at initiation of GLP1a therapy. Various
factors will need to be considered to ensure that safety and
diabetes control are maintained.
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